GlassScriptPhysician profile
Raul M Arroyo
NPI 1104926807
$3,747.58
in general payments reported to CMS, 2019-2025
17 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $56.59 · 2021: $552 · 2022: $686 · 2023: $1,138 · 2024: $336 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921 · Travel and Lodging: $795 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.38 |
| Travel and Lodging | $794.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,407.89 | 2021-2024 | Urolift |
| Boston Scientific Corporation | $510.86 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator |
| Janssen Biotech, INC. | $313.93 | 2019-2023 | Erleada |
| Janssen Pharmaceuticals, INC | $296.42 | 2019-2025 | Xarelto, Erleada |
| Olympus Latin America, INC. | $222.11 | 2025 | Tecoflex, Olympus, Olympus |
| Endomagnetics LTD | $220.77 | 2022-2023 | Magtrace, Magseed |
| Verity Pharmaceuticals INC. | $139.17 | 2023-2024 | Tlando, Trelstar |
| Travere Therapeutics, INC. | $117.64 | 2019 | |
| Urogen Pharma, INC. | $114.14 | 2022 | |
| Medtronic, INC. | $105.97 | 2024 | Micra |
| Allergan, INC. | $100.00 | 2019 | |
| Kci USA, INC. | $49.17 | 2019 | |
| Tolmar, INC. | $47.77 | 2025 | Eligard, Jatenzo, Rubraca |
| Pfizer INC. | $34.86 | 2021 | |
| Abbvie INC. | $25.00 | 2023 | Lupron Depot |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaand Gmbh | $23.69 | 2025 | Rubraca |
| Ferring Pharmaceuticals INC. | $18.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Arroyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.